Helicobacter pylori infection is associated with advanced colorectal neoplasia
H. Shmuely,E. Melzer,M. Braverman,N. Domnitz,J. Yahav
DOI: https://doi.org/10.3109/00365521.2013.879336
2014-04-01
Scandinavian Journal of Gastroenterology
Abstract:To the Editor, Kountouras et al. [1] in their letter commenting on our study [2] stated that only current Helicobacter pylori infection (Hp-I) reduces humoral and cellular immune responses inducing or perpetuating chronic inflammatory processes in the gastrointestinal tract with potential oncogenic sequelae. Most malignancies, including colorectal carcinoma (CRC), occur at the chronic inflammation sites and infection. In our study [2], we used two serology tests. ELISA, validated in our laboratory, involving patients who had undergone an endoscopy at our hospital, yielded a sensitivity of 94% and specificity of 90%. Positive and negative predictive values of 100% and 90%, respectively, were observed. We also tested for IgG antibodies against CagA protein with immunoblot staining using a Western blot kit (Helicoblot 2.0; Genelabs Diagnostic, Singapore). CRC is a slow-growing cancer and it takes up to 18 years for a dysplastic cell to transform to cancer [3], and Hp-I initiates the process. The low rates of natural acquisition and elimination of Hp in adults [4] suggest that there is almost no selfelimination of the bacteria that persists throughout life; thus, serology may remain positive even after curing the infection [5]. In patients treated with antisecretory drugs, H. pylori antibodies persist. Positive antibody levels were found in 86% of patients with chronic atrophic gastritis; however, positive histology was only apparent in 33% of the subjects and in patients after gastrectomy [6]. Regarding Kountouras’ letter [1], the authors base their results on only 50 CRC patients and 25 patients with colorectal adenomas (CRAs) and only 10 controls. The number of controls is unusually low and do not represent a comparable group. The authors neither specify gender and age of patients and controls nor their socioeconomic status. As to the small number of cases, the presence of Hp-I in the CRA (68%) and CRC (84%) groups has no statistical significance in univariate analysis, especially without multivariate analysis for confounders. Only 8 out of 50 CRC and 8 out of 25 patients with CRAs were Hp negative, rendering it very difficult to reach any conclusions, especially regarding Hp eradication. The results presented by Kountouras et al. [1] indicate that Hp-I impacts colorectal oncogenesis, thus supporting our results and conclusion.